Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Shimizu Y, Terai T, Inoue H, Nakadate T, Ito C, Yoshida T, Ohno I, Tanno Y, Arakawa M, Igarashi K, Okada M, Ozaki K, Aoki N, Kitamura N, Sekine O, Suzuki Y, Nakata K, Nakatani T, Inagawa H, Kusano N
Juntendo University School of Medicine.
Jpn J Antibiot. 1998 Jul;51(7):437-74.
The bacteria isolated from the patients with lower respiratory tract infections were collected by institutions located throughout Japan, since 1981. Ikemoto et al. have been investigating susceptibilities of these isolates to various antibacterial agents and antibiotics, and characteristics of the patients and isolates from them each year. Results obtained from these investigations are discussed. In 16 institutions around the entire Japan, 557 strains of presumably etiological bacteria were isolated mainly from the sputa of 449 patients with lower respiratory tract infections during the period from October 1996 to September 1997. MICs of various antibacterial agents and antibiotics were determined against 98 strains of Staphylococcus aureus, 93 strains of Streptococcus pneumoniae, 84 strains of Haemophilus influenzae, 84 strains of Pseudomonas aeruginosa (non-mucoid strains), 17 strains of Pseudomonas aeruginosa (mucoid strains), 31 strains of Moraxella subgenus Branhamella catarrhalis, 21 strains of Klebsiella pneumoniae etc., and the drug susceptibilities of these strains were assessed except for those strains that died during transportation. 1) S. aureus S. aureus strains for which MICs of oxacillin (MPIPC) were higher than 4 micrograms/ml (methicillin-resistant S. aureus) accounted for 67.3%. The frequency of the drug resistant bacteria increased comparing to the previous year's 52.7%. Arbekacin (ABK) and vancomycin (VCM) showed the highest activities against both S. aureus and MRSA with MIC80s of 1 microgram/ml. 2) S. pneumoniae Imipenem (IPM) and panipenem (PAPM) of carbapenems showed the most potent activities with MIC80s of 0.063 microgram/ml. Faropenem (FRPM) showed the next potent activity with MIC80 of 0.125 microgram/ml. The other drugs except erythromycin (EM), clindamycin (CLDM) and tetracycline (TC) were active against S. pneumoniae tested with MIC80s of 8 micrograms/ml or below. 3) H. influenzae The activities of all drugs were potent against H. influenzae tested with MIC80s of 4 micrograms/ml or below. Cefotiam (CTM), cefmenoxime (CMX), cefditoren (CDTR) and ofloxacin (OFLX) showed the most potent activities with MIC80s of 0.063 microgram/ml. 4) P. aeruginosa (mucoid strains) Tobramycin (TOB) showed the most potent activity against P. aeruginosa (mucoid strains) with MIC80 of 1 microgram/ml. Ceftazidime (CAZ), cefsulodin (CFS), IPM, gentamicin (GM), ABK and ciprofloxacin (CPFX) showed the next potent activities, with MIC80s of 2 micrograms/ml. The MIC80s of the other drugs ranged from 4 micrograms/ml to 16 micrograms/ml. 5) P. aeruginosa (non-mucoid strains) TOB and CPFX showed the most potent activities against P. aeruginosa (non-mucoid strains) with MIC80s of 1 microgram/ml. The MIC80s of piperacillin (PIPC) and cefoperazone (CPZ) were 16 micrograms/ml in 1995, and they were 64 micrograms/ml in 1996. 6) K. pneumoniae All drugs except ampicillin (ABPC) were active against K. pneumoniae. CMX, cefpirome (CPR), cefozopran (CZOP) and carumonam (CRMN) showed the most potent activities against K. pneumoniae with MIC80s of 0.125 microgram/ml. The MIC80s of the other drugs ranged from 0.25 microgram/ml to 2 micrograms/ml. 7) M.(B) catarrhalis Against M.(B.) catarrhalis, all drugs showed good activities with MICs of 4 micrograms/ml or below. IPM and minocycline (MINO) showed the most potent activities with MICs of 0.063 microgram/ml. Also, we investigated year to year changes in the characteristics of patients, their respiratory infectious diseases, and the etiology. Patients' backgrounds were examined for 557 isolates from 449 cases. The examination of age distribution indicated that the proportion of patients with ages over 60 years was 71.0% of all the patients showing a slight increase over that in 1994. Proportions of diagnosed diseases were as follows: Bacterial pneumonia and chronic bronchitis were the most frequent with 35.9% and 30.3% respectively. They were followed by bronchiectasis with a proportion of 10.
自1981年起,日本各地的机构收集了从下呼吸道感染患者中分离出的细菌。池本等人每年都在研究这些分离菌株对各种抗菌剂和抗生素的敏感性,以及患者及其分离菌株的特征。讨论了这些调查的结果。在全日本的16个机构中,1996年10月至1997年9月期间,主要从449名下呼吸道感染患者的痰液中分离出557株可能的病原菌。测定了各种抗菌剂和抗生素对98株金黄色葡萄球菌、93株肺炎链球菌、84株流感嗜血杆菌、84株铜绿假单胞菌(非黏液型菌株)、17株铜绿假单胞菌(黏液型菌株)、31株莫拉菌属卡他莫拉菌、21株肺炎克雷伯菌等的最低抑菌浓度(MIC),并评估了这些菌株的药敏情况,但不包括运输过程中死亡的菌株。1)金黄色葡萄球菌 苯唑西林(MPIPC)的MIC高于4微克/毫升的金黄色葡萄球菌菌株(耐甲氧西林金黄色葡萄球菌)占67.3%。与上一年的52.7%相比,耐药菌的频率有所增加。阿贝卡星(ABK)和万古霉素(VCM)对金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌的活性最高,MIC80均为1微克/毫升。2)肺炎链球菌 碳青霉烯类的亚胺培南(IPM)和帕尼培南(PAPM)活性最强,MIC80为0.063微克/毫升。法罗培南(FRPM)活性次之,MIC80为0.125微克/毫升。除红霉素(EM)、克林霉素(CLDM)和四环素(TC)外,其他药物对肺炎链球菌的MIC80均在8微克/毫升或以下,具有活性。3)流感嗜血杆菌 所有药物对流感嗜血杆菌的活性均较强,MIC80均在4微克/毫升或以下。头孢替安(CTM)、头孢甲肟(CMX)、头孢妥仑(CDTR)和氧氟沙星(OFLX)活性最强,MIC80为0.063微克/毫升。4)铜绿假单胞菌(黏液型菌株) 妥布霉素(TOB)对铜绿假单胞菌(黏液型菌株)活性最强,MIC80为1微克/毫升。头孢他啶(CAZ)、头孢磺啶(CFS)、IPM、庆大霉素(GM)、ABK和环丙沙星(CPFX)活性次之,MIC80为2微克/毫升。其他药物的MIC80在4微克/毫升至16微克/毫升之间。5)铜绿假单胞菌(非黏液型菌株) TOB和CPFX对铜绿假单胞菌(非黏液型菌株)活性最强,MIC80为1微克/毫升。哌拉西林(PIPC)和头孢哌酮(CPZ)的MIC80在1995年为16微克/毫升,1996年为64微克/毫升。6)肺炎克雷伯菌 除氨苄西林(ABPC)外,所有药物对肺炎克雷伯菌均有活性。CMX、头孢匹罗(CPR)、头孢唑兰(CZOP)和卡芦莫南(CRMN)对肺炎克雷伯菌活性最强,MIC80为0.125微克/毫升。其他药物的MIC80在0.25微克/毫升至2微克/毫升之间。7)卡他莫拉菌 所有药物对卡他莫拉菌均有良好活性,MIC均在4微克/毫升或以下。IPM和米诺环素(MINO)活性最强,MIC为0.063微克/毫升。此外,我们还研究了患者特征、呼吸道传染病及其病因的逐年变化。对449例患者的557株分离菌株进行了患者背景调查。年龄分布检查表明,60岁以上患者占所有患者的比例为71.0%,比